KBR, BIV Builders Sign Joint Venture Agreement

KBR, BIV Builders Sign Joint Venture Agreement

KBR said Wednesday it has signed a joint venture agreement with BIV Builders for a standalone, self-sufficient, long-term joint venture based in Kuala Lumpur, Malaysia. The joint venture will be known as KBIV. Financial details of the deal were not disclosed. “Our customers expect us to work locally and draw on our global resources and systems to deliver innovative and technologically superior solutions; the establishment of KBIV is our delivery […]

Read More ˃
ArQule Shares Rise

ArQule Shares Rise

ArQule shares surged 44% on Thursday after the company said pre-clinical data on ARQ 531 in in diffuse large B-cell lymphoma demonstrated “potent” anti-tumor activity. The company said the data support clinical trials with ARQ 531 in the ibrutinib resistant patient population. A phase 1 trial with ARQ 531 in patients with B-cell malignancies refractory to other therapeutic options, including ibrutinib, is planned to commence by the third quarter of […]

Read More ˃
TearLab Gets Brazilian Regulatory Ok

TearLab Gets Brazilian Regulatory Ok

TearLab Corp. said pre-market Friday it secured approval in Brazil for its Osmolarity System, allowing it to begin selling the product in the country, which is intended to help in the diagnosis of dry eye disease. The company said it is currently working to finalize its distribution and launch plans in Brazil and expects to launch the system in Q3. “We are pleased that this approval was received well ahead […]

Read More ˃
Spark Energy Q1 Profit Down on Higher Revenues

Spark Energy Q1 Profit Down on Higher Revenues

Spark Energy reported Monday Q1 net profit of $2.3 million, down from $4.2 million reported for the same period last year, below of the $4.5 million Street estimate. Revenues were $194.3 million, up from $110.5 million reported for the same period last year and better than the $146.3 million estimate from analysts polled by Capital IQ. For 2017, the company expects adjusted EBITDA to range from $110 million to $120 […]

Read More ˃
Soligenix Gets FDA OK for Phase 3 Trial

Soligenix Gets FDA OK for Phase 3 Trial

Soligenix Inc., a late-stage biopharmaceutical company, said Wednesday it has received U.S. Food and Drug Administration clearance to advance a pivotal phase 3 clinical trial evaluating SGX942 (dusquetide) for the treatment of oral mucositis in head and neck cancer (HNC) patients being treated with chemoradiation (CRT). Shares were up over 11% in recent pre-market trade, Soligenix plans to begin this study in Q2. The primary endpoint for the study will […]

Read More ˃